SSII is rapidly growing its surgical robotics business, with strong revenue and KPI growth while expanding into new international markets. Despite operating losses and dilution risk, I see a path to profitability as installations and instrument sales accelerate. The stock is aggressively valued, but industry-leading growth and sector hype justify a speculative buy for risk-tolerant investors.
Surgery performed by Dr. Juan Zuniga at Interhospital in Guayaquil, Ecuador PR Audio: Fort Lauderdale, FL, June 16, 2025 – PRISM MediaWire – SS Innovations International, Inc.
SS Innovations Announces Completion of First Robotic Cardiac Surgery in the Western Hemisphere Utilizing the Company's SSi Mantra 3 Surgical Robotic System
13 May 2025 Date | | - Cons. EPS | - EPS |
20 Mar 2025 Date | | - Cons. EPS | - EPS |
11 Nov 2024 Date | | - Cons. EPS | - EPS |
12 Aug 2024 Date | | - Cons. EPS | - EPS |
7 Aug 2024 Date | | - Cons. EPS | - EPS |
13 May 2025 Date | | - Cons. EPS | - EPS |
20 Mar 2025 Date | | - Cons. EPS | - EPS |
11 Nov 2024 Date | | - Cons. EPS | - EPS |
12 Aug 2024 Date | | - Cons. EPS | - EPS |
7 Aug 2024 Date | | - Cons. EPS | - EPS |
Medical - Devices Industry | Healthcare Sector | Sudhir Prem Srivastava CEO | NASDAQ (CM) Exchange | US05453U2033 ISIN |
US Country | 378 Employees | - Last Dividend | 17 Apr 2023 Last Split | - IPO Date |